JAMP LATANOPROST SOLUTION

Држава: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

LATANOPROST

Доступно од:

JAMP PHARMA CORPORATION

АТЦ код:

S01EE01

INN (Међународно име):

LATANOPROST

Дозирање:

50MCG

Фармацеутски облик:

SOLUTION

Састав:

LATANOPROST 50MCG

Пут администрације:

OPHTHALMIC

Јединице у пакету:

5ML

Тип рецептора:

Prescription

Терапеутска област:

PROSTAGLANDIN ANALOGS

Резиме производа:

Active ingredient group (AIG) number: 0132916001; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2019-01-08

Карактеристике производа

_JAMP Latanoprost ( latanoprost)_ Page 1 of 29
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
JAMP LATANOPROST
Latanoprost ophthalmic solution
Solution, 50 mcg/mL, Ophthalmic
Prostaglandin F
2α
analogue
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
June 09, 2022
Date of Revision:
July 05, 2023
Submission Control Number: 273490
_JAMP Latanoprost ( latanoprost)_ Page 2 of 29
_ _
RECENT MAJOR LABEL CHANGES
None at the time of most recent authorization
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES...........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
...............................................................................................
4
4
DOSAGE AND ADMINISTRATION
...............................................................................
4
4.1
Dosing Considerations
.............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
........................................................ 4
4.4
Administration
.........................................................................................................
5
4.5
Missed Dose
...........................................................